The Treatment of Peritoneal Carcinomatosis in Advanced Gastric Cancer: State of the Art

Table 1

Comparing main studies in terms of median survival, 5-year survival rates, and morbidity.


Authors	Year published	Type of study	Stage of GC	Number of patients	Type of protocol	Median survival (months)	5-year survival rates	Morbidity

Fujimoto et al. [21]	1999	RCT	Stage II-III	141	HIPEC + surgery versus surgery alone	N/A	76% versus 57%	N/A
Kim and Bae [7]	2001	PCS	Stage III-IV	103	HIPEC + CRS versus surgery alone	36 versus 22.9	32.7% versus 27.1%	33.2% versus 36.5%
Yonemura et al. [8]	2001	RCT	Stage II-III	139	HIPEC + surgery versus NIC + surgery versus surgery alone	N/A	61% versus 43% versus 42%	4% versus 0% versus 4%
Yonemura et al. [9]	2009	PCS	Stage III-IV	79	NIPS versus NIPS + surgery	N/A	20.4% versus 40%*	11.4%
Glehen et al. [10]	2010	RCS	Stage III-IV	159	HIPEC + EPIC versus EPIC HIPEC	9.2 (overall)	13% (overall)	27.8% (overall)

HIPEC: hyperthermic intraperitoneal chemotherapy; EPIC: early postoperative intraperitoneal chemotherapy; PIC: perioperative intraperitoneal chemotherapy; NIC: normothermic intraperitoneal chemotherapy; NIPS: neoadjuvant intraperitoneal and systemic chemotherapy; NIIC: normothermic Intraoperative Intraperitoneal Chemotherapy; DPIC: Delayed Postoperative Intraperitoneal Chemotherapy; RCS: Retrospective Case Series; PCS: Prospective cohort study; PCS: prospective case series; N/A: not available.
*2-year survival rates.

International Journal of Surgical Oncology

The Treatment of Peritoneal Carcinomatosis in Advanced Gastric Cancer: State of the Art

Table 1